Abstract:Abstract Background Triple negative breast cancer (TNBC) remains the most challenging breast cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical improvements in treatment of TNBC patients and effective molecular biomarkers are largely unknown. Methods We used paired TNBC samples and high throughput RNA sequencing to identify differentially expressed circRNAs. Sucrose gradient polysome fractionation assay, antibody and Mass spectra were used to validate active circRNA translation. The novel protein function was validated in vitro and in vivo by gain or loss of function assays. Mechanistic results were concluded by immunoprecipitation analyses and kinase activity assay. Results Circular HER2 RNA (circ-HER2) encoded a novel protein, HER2–103. Unexpectedly, while HER2 mRNA and protein were barely detected, circ-HER2/HER2–103 was expressed in ~ 30% TNBC clinical samples. Circ-HER2/HER2–103 positive TNBC patients harbored worse overall prognosis than circ-HER2/HER2–103 negative patients. Knockdown circ-HER2 inhibited TNBC cells proliferation, invasion and tumorigenesis in vitro and in vivo, suggesting the critical role of circ-HER2/HER2–103 in TNBC tumorigenicity. Mechanistically, HER2–103 promoted homo/hetero dimerization of epidermal growth factor receptor (EGFR)/HER3, sustained AKT phosphorylation and downstream malignant phenotypes. Furthermore, HER2–103 shared most of the same amino acid sequences as HER2 CR1 domain which could be antagonized by Pertuzumab, a clinical used HER2 antibody. Pertuzumab markedly attenuated in vivo tumorigenicity of circ-HER2/HER2–103 expressing TNBC cells but showed no effects in circ-HER2/HER2–103 negative TNBC cells. Conclusion Our results not only demonstrated that certain TNBCs were not truly ‘HER2 negative’ but also highlighted the clinical implications of Pertuzumab in circ-HER2/HER2–103 expressing TNBC patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether there are new therapeutic targets in triple - negative breast cancer (TNBC). Specifically, the researchers discovered a special circular RNA - circ - HER2 in some TNBC patients, which encodes a new protein HER2 - 103. Although the expression levels of HER2 mRNA and protein in these patients are very low, circ - HER2/HER2 - 103 is expressed in approximately 30% of TNBC clinical samples. The study further found that HER2 - 103 promotes tumorigenesis in TNBC by promoting the homodimerization or heterodimerization of epidermal growth factor receptor (EGFR)/HER3, maintaining AKT phosphorylation and downstream malignant phenotypes. In addition, HER2 - 103 shares most of the same amino acid sequence with the CR1 domain of HER2 and can be antagonized by the clinically used HER2 antibody Pertuzumab. Therefore, the study aims to explore the inhibitory effect of Pertuzumab on TNBC cells expressing circ - HER2/HER2 - 103 and the clinical significance of this finding for TNBC patients. ### Summary of main problems: 1. **Identification of new therapeutic targets**: The study attempts to determine whether there are new molecular markers in TNBC, especially circ - HER2 and its encoded HER2 - 103 protein. 2. **Validation of circ - HER2 function**: The study verified the function of circ - HER2/HER2 - 103 in TNBC through multiple experimental methods, including its effects on cell proliferation, invasion and tumorigenesis. 3. **Evaluation of Pertuzumab efficacy**: The study explored the inhibitory effect of Pertuzumab on TNBC cells expressing circ - HER2/HER2 - 103 and the potential significance of this finding for clinical treatment. ### Research background: - **Characteristics of TNBC**: TNBC lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu proto - oncogene, and has high invasiveness and poor prognosis. - **Limitations of existing treatments**: At present, the targeted therapy for TNBC has poor efficacy, and chemotherapy is still the standard treatment method. - **Research progress of circRNA**: circRNA plays an important role in various diseases, but its function in TNBC has not been fully clarified. ### Research methods: - **High - throughput sequencing**: Paired TNBC samples were used for high - throughput RNA sequencing to identify differentially expressed circRNAs. - **Function verification**: The function of circ - HER2/HER2 - 103 was verified by knockdown and overexpression experiments. - **Mechanism study**: The mechanism of action of HER2 - 103 was explored by immunoprecipitation analysis and kinase activity assay methods. - **Drug testing**: The inhibitory effect of Pertuzumab on TNBC cells expressing circ - HER2/HER2 - 103 was evaluated. ### Main results: - **Identification of circ - HER2**: The expression of circ - HER2/HER2 - 103 was detected in approximately 30% of TNBC clinical samples. - **Function verification**: Knockdown of circ - HER2 inhibited the proliferation, invasion and tumorigenesis of TNBC cells. - **Mechanism analysis**: HER2 - 103 maintains AKT phosphorylation and downstream malignant phenotypes by promoting the dimerization of EGFR/HER3. - **Efficacy of Pertuzumab**: Pertuzumab significantly inhibited the tumorigenesis of TNBC cells expressing circ - HER2/HER2 - 103, but had no obvious effect on TNBC cells not expressing circ - HER2/HER2 - 103. ### Conclusions: - **TNBC is not truly "HER2 - negative"**: Although some TNBC patients have low expression of HER2 mRNA and protein, there is expression of circ - HER2/HER2 - 103. - **Clinical significance of Pertuzumab**: Pertuzumab may have therapeutic potential for TNBC patients expressing circ - HER2/HER2 - 103. Hope this information is helpful for you to understand this paper! If you have more questions, feel free to continue asking.

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab

CircRNA hsa_circ_0006220 acts as a tumor suppressor gene by regulating miR-197-5p/CDH19 in triple-negative breast cancer

Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models

The Circular RNA circFGFR4 Facilitates Resistance to Anti-PD-1 of Triple-Negative Breast Cancer by Targeting the miR-185-5p/CXCR4 Axis

CircZCCHC2 Decreases Pirarubicin Sensitivity and Promotes Triple-Negative Breast Cancer Development Via the Mir-1200/Tpr Axis

Circ_0001777 Affects Triple-negative Breast Cancer Progression Through the miR-95-3p/AKAP12 Axis

Circular RNA: A Potential Diagnostic, Prognostic, and Therapeutic Biomarker for Human Triple-Negative Breast Cancer

Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis

CircEIF3H-IGF2BP2-HuR Scaffold Complex Promotes TNBC Progression Via Stabilizing HSPD1/RBM8A/G3BP1 Mrna.

CircEGFR Reduces the Sensitivity of Pirarubicin and Regulates the Malignant Progression of Triple-Negative Breast Cancer Via the Mir-1299/Egfr Axis

Circular RNA dehydrodolichyl diphosphate synthase facilitated triple‐negative breast cancer progression via miR ‐362‐3p/ DDX5 axis

Hsa_circ_0000199 Facilitates Chemo-Tolerance of Triple-Negative Breast Cancer by Interfering with Mir-206/613-led PI3K/Akt/mTOR Signaling.

CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis

Circular RNA Circ-Erbb2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5P/pyruvate Dehydrogenase Kinase 4 Axis.

Peptidylprolyl isomerase D circular RNA sensitizes breast cancer to trastuzumab through remodeling HER2 N4-acetylcytidine modification

Circepsti1 As a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression

CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes

MiR-92b-3p Inhibits Proliferation of HER2-Positive Breast Cancer Cell by Targeting circCDYL

Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape

Circrad18 Sponges Mir-208A/3164 to Promote Triple-Negative Breast Cancer Progression Through Regulating IGF1 and FGF2 Expression.